Overview

Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma

Status:
Terminated

Trial end date:
2009-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the impact of Trans Sodium Crocetinate (TSC) on oxygen levels in brain tumor tissue in patients with high grade glioma. The proposed clinical indication for TSC is a radiation sensitizer for the treatment of cancerous tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Diffusion Pharmaceuticals Inc
Diffusion Pharmaceuticals LLC

Treatments:

Trans-sodium crocetinate
Vitamin A